| Literature DB >> 28859643 |
Takuma Narita1, Shingo Hatakeyama2, Takuya Koie1, Shogo Hosogoe1, Teppei Matsumoto1, Osamu Soma1, Hayato Yamamoto1, Tohru Yoneyama3, Yuki Tobisawa1, Takahiro Yoneyama1, Yasuhiro Hashimoto3, Chikara Ohyama1,3.
Abstract
BACKGROUND: Urinary tract obstruction and postoperative hydronephrosis are risk factor for renal function deterioration after orthotopic ileal neobladder construction. However, reports of relationship between transient hydronephrosis and renal function are limited. We assess the influence of postoperative transient hydronephrosis on renal function in patients with orthotopic ileal neobladder construction.Entities:
Keywords: Hydronephrosis; Ileal neobladder; Radical cystectomy; Renal function; eGFR
Mesh:
Year: 2017 PMID: 28859643 PMCID: PMC5580195 DOI: 10.1186/s12894-017-0263-x
Source DB: PubMed Journal: BMC Urol ISSN: 1471-2490 Impact factor: 2.264
Fig. 1Hydronephrosis grade and stratification. a. The hydronephrosis grade of each renal unit was evaluated by computed tomography (CT) imaging, and scored according to hydronephrosis grading scale: grade 0, no dilatation (G0); grade 1, pelvic dilatation only (G1); grade 2, mild caliceal dilatation (G2); grade 3, severe caliceal dilatation (G3); and grade 4, renal parenchymal atrophy (G4). b. Patients were stratified into 4 groups according to hydronephrosis grade and status (unilateral or bilateral): no hydronephrosis in bilateral kidneys (control group), unilateral hydronephrosis (low group), bilateral hydronephrosis with G1 or G2 (intermediate group), and bilateral hydronephrosis with G3 or G4 on either side (high group)
Clinical and pathological patient characteristics
| All | Hydronephrosis stratification at 1 M |
| ||||
|---|---|---|---|---|---|---|
| Control | Low | Intermediate | High | |||
| n | 64 | 12 | 11 | 27 | 14 | |
| Agea | 66 (61–71) | 63 (55–69) | 69 (60–73) | 67 (59–71) | 69 (63–75) |
|
| Gender (Male/Female), n= | 48 / 16 | |||||
| ECOG-PS | 0.0 (0–0) | 0.0 (0–0) | 0.0 (0–0) | 0.0 (0–0) | 0.0 (0–0) |
|
| Past history, n= | ||||||
| Cardiovascular disease | 6 (9%) | 1 ((%) | 1 (9%) | 3 (11%) | 1 (7%) |
|
| Hypertension | 21 (33%) | 3 (25%) | 3 (27%) | 11 (41%) | 4 (29%) |
|
| Diabetes | 9 (14%) | 1 (8%) | 2 (18%) | 5 (19%) | 1 (7%) |
|
| Neoadjuvant chemotherapy, n= | 61 (95%) | 11 (92%) | 11 (100%) | 26 (96%) | 13 (93%) |
|
| Clinical T stagea | 2 (2–3) | 3 (2–3) | 2 (2–3) | 2 (2–3) | 3 (2–3) |
|
| Pathological T stagea | 1 (0–2) | 2 (0–2) | 1 (0–2) | 2 (1–2) | 2 (0–2) |
|
| Pathological N+, n= | 2 (3%) | 0 (0%) | 0 (0%) | 1 (4%) | 1 (7%) |
|
| eGFRa | ||||||
| Before surgery | 73 (66–87) | 77 (75–97) | 84 (73–91) | 72 (65–88) | 69 (62–73) |
|
| 1 month after surgery | 60 (53–74) | 71 (57–82) | 73 (60–88) | 58 (52–65) | 56 (43–72) |
|
| 1 year after surgery | 65 (56–74) | 69 (62–76) | 63 (53–78) | 63 (53–74) | 69 (61–75) |
|
| Hydronephrosis gradesa | ||||||
| Before surgery | 0 (0–0) | 0 (0–1) | 0 (0–0) | 0 (0–0) | 0 (0–0) |
|
| 1 month after surgery | 2 (0–2) | 0 (0–0) | 1 (0–2) | 2 (2–2) | 3 (3–3) |
|
| 1 year after surgery | 0 (0–1) | 0 (0–0) | 0 (0–1) | 0 (0–0) | 1 (0–1) |
|
| Complications (any grades), n= | 16 (25%) | 2 (17%) | 3 (27%) | 10 (37%) | 1 (7%) | 0.213 |
| Complications (Clavien Grade > 3), n= | 2 (2%) | 0 (0%) | 1 (9%) | 1 (4%) | 0 (0%) | 0.261 |
| Operative durationa (min) | 294 (266–323) | 281 (237–303) | 277 (263–300) | 322 (273–356) | 280 (265–307) |
|
| Blood lossa (g) | 1380 (1034–2302) | 1345 (576–2211) | 1400 (1070–2465) | 1470 (926–2350) | 1430 (1095–2359) |
|
| Recurrence (within 1 year), n= | 2 (3%) | 0 (0%) | 2 (18%) | 0 (0%) | 0 (0%) |
|
amedian (Q1-Q3)
Q1, first quartile; Q3, third quartile;b Kruskal–Wallis test;c Fisher’s exact test
Fig. 2Preoperative and postoperative hydronephrosis grades. a. The overall hydronephrosis grades in 128 renal units were increased significantly 1 month after surgery (P < 0.001), but improved significantly 1 year after surgery (P < 0.001). b. The hydronephrosis grades in the low group did not changed significantly (P = 0.3145). The hydronephrosis grades in the intermediate and high groups were significantly increased 1 month after surgery (P < 0.0001), but improved significantly 1 year after surgery (P < 0.001). Statistical analyses were performed using Wilcoxon matched-pairs signed rank test
Fig. 3Preoperative and postoperative eGFR. a. No significant changes were observed in renal function before surgery and 1 month after surgery (P = 0.0977) or 1 month and 1 year after surgery (P = 0.9097) in the control group. b and c. The presence of mild hydronephrosis 1 month after surgery was significantly associated with renal function decline in the low (P = 0.0117) and intermediate (P = 0.0001) groups. Renal function became stable 1 year after surgery. d. The presence of severe hydronephrosis 1 month after surgery was significantly associated with a decline in renal function in the high group (P = 0.0005). However, renal function recovered significantly 1 year after surgery (P = 0.0083). Statistical analyses were performed using Wilcoxon matched-pairs signed-rank test
Fig. 4Intergroup postoperative eGFR differences compared with control. a. One month after surgery, postoperative eGFR was significantly lower in the high group. b. One year after surgery, postoperative eGFR was not significantly different between the high and control groups. Statistical analyses were performed using Mann–Whitney U test
Univariate and multivariate logistic regression analyses of the risk factors for eGFR <60 mL/min/1.73 m2 at 1 year after surgery
| Univariate | Risk factors |
| Odds ratio | 95% CI |
| Age | > 65.5 years |
| 2.4 | 0.8–7.3 |
| Gender | Male |
| 1.0 | 0.3–3.4 |
| Past history of | ||||
| Cardiovascular disease | Positive |
| 0.4 | 0.0–3.8 |
| Hypertension | Positive |
| 0.8 | 0.3–2.6 |
| Diabetes | Positive |
| 1.9 | 0.5–8.2 |
| Pathological T stage | pT3, 4 |
| 0.7 | 0.1–3.8 |
| Pathological N status | pN+ |
| 2.3 | 0.1–38.1 |
| Hydronephrosis at 1 M | > low |
| 2.1 | 0.6–6.7 |
| Neoadjuvant chemotherapy | received |
| 0.9 | 0.1–10.6 |
| Preoperative eGFR | < 60 |
| 7.0 | 1.2–40 |
| Postoperative eGFR at 1 M | < 60 |
| 7.7 | 2.2–27 |
| Complications (any grade) | Positive |
| 1.5 | 0.4–4.8 |
| Operative duration | > 294 |
| 3.4 | 1.1–10 |
| Blood loss (g) | > 1380 |
| 2.4 | 0.8–7.3 |
| Recurrence | Positive |
| 2.3 | 0.1–38.1 |
| Multivariate | Risk factors |
| Odds ratio | 95% CI |
| Age | > 65.5 years |
| 1.2 | 1.1–1.5 |
| Gender | Male |
| 0.7 | 0.5–0.9 |
| Hydronephrosis at 1 M | > low |
| 0.4 | 0.7–1.1 |
| Preoperative eGFR | < 60 |
| 3.7 | 0.4–34.0 |
| Postoperative eGFR at 1 M | < 60 |
| 9.0 | 1.9–42.4 |
| Operative duration | > 294 |
| 6.2 | 1.3–29.3 |